Research Paper Volume 16, Issue 5 pp 4445—4468

Figure 1. The expression of FIGN in hepatocellular carcinoma and pan-carcinoma. (A) The mRNA expression of FIGN was downregulated in 14 of 21 cancer types compared with normal tissues. Difference in expression of FIGN between HCC and normal tissues in TCGA data sets (B), GSE121248 (C) and GSE25097 (D). (E) Relative mRNA expression in HCC and paracarcinoma tissues. N=30. (F) Protein levels of FIGN in HCC and adjacent normal tissues. (G) Relative gray density analysis on bands of Figure F. (H–I) Immunohistochemistry assay to detect the expression of FIGN in HCC and paracarcinoma tissues. (H) was negative control. N=3, scale bar=100μM. (J) Difference in FIGN IHC score in HCC and matched paracarcinoma tissue. The two groups were compared using t-tests. *P < 0.05, **P < 0.01, ***P < 0.001, ns, no significance. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; READ, rectum adenocarcinoma; SARC, Sarcoma; SKCM, skin Cutaneous Melanoma; THCA, thyroid carcinoma; THYM, thymoma; STAD, stomach adenocarcinoma; UCEC, uterine corpus endometrial carcinoma.